Experiments were conducted essentially the same way as described in Figure 4 , except that the siRNA used in the study was designed to target β-actin, rather than VEGF2 gene.
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Tumor-bearing mice were injected with Cy5-labeled cRGD-siRNA intravenously six times, once every two days (1 nmol/injection), and the whole animals (left panel) or individually isolated organs/tumors (right panel) were bio-imaged two days after the last injections. Tumor samples were then analyzed for knockdown of β-actin mRNA using RT-qPCR (B B B B) and of corresponding protein using quantitative Western blotting (C C C C). All results were compiled from triplicate data sets. Double stars (**) denote the P<0.01 values. Figure Figure Figure cRGD-siRNA1 (1 nmol/injection) or saline every three days for a total of six times. Serum was collected two days after the last injection and analyzed for the alanine aminotransferase activity (ALT; IU/L; indicator of liver toxicity) and creatinine levels (Cr; μmol/L; indicator of renal health). In all experiments three animals were used per each treatment. Table Table Table Table S1 . S1. S1. S1. Sequences of qRT-PCR primers used in the study Table Table Table Table S2 Table Table Table Table S3A . S3A. S3A. S3A. Cytokine levels in mouse sera 6 hours after treatment (n=3, mean±SD) Table Table Table Table S3B 
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